Beijing Advances Implementation of Medical and Health Innovation Plan; Zai Lab Reports 39% YoY Revenue Growth in Q1
Zai Lab
Innovative Global Biopharmaceutical Company
Qihan Biotech
Gene Editing Technology Developer
The warm breeze of innovative drugs continues to blow.
On May 8, the Standing Committee of the Beijing Municipal Party Committee held a meeting, emphasizing the need to promote the implementation of the Action Plan for Accelerating the Coordinated Innovation of Medicine and Health, with the aim of building a modern pharmaceutical industry cluster with global influence; further strengthening the basic pharmaceuticals sector, expediting the market entry of innovative drugs, expanding the medical device industry, attracting international projects, enhancing production and manufacturing capabilities, and advancing research on Beijing's Action Plan for Accelerating the Coordinated Innovation of Medicine and Health.
Zai Lab Continues High Growth.
On May 9, Zai Lab released its Q1 2024 report. During the reporting period, the company's revenue was $87.1 million, a year-on-year increase of 39%.
What are the hot topics worth paying attention to in the pharmaceutical market at home and abroad in the past day? Let Amino take you through them.
/ 01 /
Market Express
1) The Standing Committee of the Beijing Municipal Party Committee held a meeting: to study the action plan for accelerating the coordinated innovation of the pharmaceuticals and health industry in the city, etc.
On May 8, the Standing Committee of the Beijing Municipal Party Committee held a meeting. The meeting emphasized the need to advance the implementation of the Action Plan for Accelerating the Collaborative Innovation of Medicine and Health, with the goal of building a modern pharmaceutical industry cluster with global influence. Further strengthen the foundational sector of pharmaceuticals, expedite the market launch of innovative drugs, expand the medical device industry, attract international projects, and enhance production and manufacturing capabilities. Actively explore new fields such as targeted therapy and immunotherapy, and vigorously cultivate leading enterprises.
2) Hangzhou Qihan Biotech Co., Ltd. Appoints New Chief Medical Officer
On May 9, Hangzhou Qihan Biotech Co., Ltd. announced that Mr. Xu Yingyong has joined the company and will serve as the Chief Medical Officer. According to the introduction, Qihan Biotech is a biotechnology company dedicated to applying high-throughput gene editing technology in the fields of cell therapy and organ transplantation.
/ 02 /
Capital LetterCease
1) Zai Lab's Q1 Revenue Reaches $87.1 Million
On May 9, Zai Lab released its Q1 2024 report. During the reporting period, the company's revenue was $87.1 million, a year-on-year increase of 39%.
2) Vice General Manager of Tonghua Dongbao Pharmaceutical Co., Ltd. Plans to Reduce No More Than 70,000 Company Shares
On May 9, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that on May 9, 2024, the company received the "Notice of Share Reduction Plan by Senior Management" from Chen Hong, the company's vice general manager. Chen Hong plans to reduce no more than 70,000 shares through centralized bidding within three months after 15 trading days from the disclosure of this reduction plan announcement (no reduction during the window period). The reduction ratio accounts for 0.0035% of the company's total share capital and 24.0678% of the shares personally held by Chen Hong.
/ 03 /
Pharmaceuticals and Medical Devices Updates
1) Bolin Pharmaceutical's BW-20507 Injection Approved for Clinical Trials
On May 9, according to the CDE website, Hangzhou Bolin Pharmaceutical Technology Co., Ltd.'s BW-20507 injection was approved for clinical trials, aiming to conduct research on the treatment of chronic hepatitis B virus infection.
2) Jiangxi Qingfeng Pharmaceutical Industry Co., Ltd.'s GP681 Dry Suspension Approved for Clinical Trials
On May 9, according to the CDE official website, Jiangxi Qingfeng Pharmaceutical Industry Co., Ltd.'s GP681 Dry Suspension was approved for clinical trials, intended for use in adult and pediatric patients aged 2 years and above, including adolescents, with uncomplicated influenza A and B.
3) Ruijikang Bio RJK002 Injection Approved for Clinical Trials
On May 9, according to the CDE official website, Ruijikang Bio's RJK002 injection has been approved for clinical trials, intended for the treatment of amyotrophic lateral sclerosis.
4) Sanofi's Itepekimab Injection Approved for Clinical Use
On May 9, according to the CDE official website, Sanofi's Itepekimab Injection has been approved for clinical trials, intended for the treatment of patients with non-cystic fibrosis bronchiectasis (NCFB).
5) Relugolix for Injection by Nuoqiao Pharmaceuticals Approved for Clinical Use
On May 9, according to the CDE official website, Relugolix Injection developed by Zai Lab has been approved for clinical trials, intended for prostate cancer patients requiring androgen deprivation therapy.
6) AstraZeneca's Budesonide and Sulfate Salbutamol Inhalation Aerosol Approved for Clinical Use
On May 9, according to the CDE website, AstraZeneca's Budesonide and Sulfate Salbutamol Inhalation Aerosol was approved for clinical use, intended for on-demand treatment and prevention of bronchoconstriction in asthma patients aged 12 years and above.
7) Yunhe Pharmaceuticals' INR101 Injection Approved for Clinical Trials
On May 9, according to the CDE official website, Yunhe Pharmaceuticals' INR101 injection was approved for clinical use and is intended for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer.
8) Amgen's AMG 451 Approved for Clinical Trials
On May 9, according to the CDE website, Amgen's AMG 451 was approved for clinical trials, with plans to conduct research on asthma treatment.
9) Zai Lab's SIPI6398 Tablets Approved for Clinical Trials
On May 9, according to the CDE official website, Zai Lab's SIPI6398 tablet has been approved for clinical trials, aiming to conduct research on the treatment of depression.
10) Laekang Pharmaceutical's LAE102 Injection Approved for Clinical Trials
On May 9, according to the CDE website, Laekang Pharmaceutical's LAE102 injection has been approved for clinical trials, aiming to conduct research on the treatment of overweight and/or obesity.
11) ENN0403 Capsule of Yino Pharmaceutical Approved for Clinical Trials
On May 9, according to the CDE official website, Yi Nuo Pharmaceutical's ENN0403 capsule was approved for clinical trials, aiming to conduct research on the treatment of cardiac surgery-associated acute kidney injury.
12) Quanxin Bio QX013N Injection Approved for Clinical Trials
On May 9, according to the CDE official website, Quanxin Biotech's QX013N injection has been approved for clinical trials, intending to conduct research on the treatment of chronic spontaneous urticaria.
13) Sanofi's Amlitelimab Injection Approved for Clinical Use
On May 9, according to the CDE official website, Sanofi's Amlitelimab injection has been approved for clinical trials. It is intended for the treatment of patients aged 12 years and above with moderate to severe atopic dermatitis who are not well controlled by topical prescription drugs or for whom the use of topical prescription drugs is not recommended.
14) Pfizer PF-07220060 Approved for Clinical Trials
On May 9, according to the CDE official website, Pfizer's PF-07220060 was approved for clinical trials and is proposed to be used in combination with PF-07850327 for the treatment of patients with estrogen receptor-positive/human epidermal growth factor receptor-negative (ER+/HER2-) advanced or metastatic breast cancer.
15) China Resources Tianqing's PD-L1 Monoclonal Antibody Approved for Marketing
On May 9, China Biologic Products announced that its direct subsidiary, Zhengda Tianqing's PD-L1 monoclonal antibody, Bemarituzumab Injection, has been approved for marketing. The indication is for first-line treatment of patients with extensive-stage small cell lung cancer in combination with Anlotinib Hydrochloride Capsules, Carboplatin, and Etoposide.
16) Wisegen Bio's EB Virus-Related Tumor mRNA Vaccine Receives FDA Clinical Trial Approval
Recently, WestGene Bio announced that its EB virus-related tumor mRNA vaccine has received FDA clinical trial approval.
17) Eisai's Perampanel Tablets Receive Approval for New Indication
On May 9, according to the NMPA website, Eisai's Perampanel Tablets received approval for a new indication, which is the treatment of tonic-clonic seizures in epilepsy.
18) Ferring Pharmaceuticals' Recombinant Human Follicle-Stimulating Hormone δ Injection Approved for Marketing
On May 9, according to the NMPA website, Ferring Pharmaceuticals' recombinant human follicle-stimulating hormone δ injection was approved for marketing in China. It is used for controlled ovarian stimulation to induce multifollicular development.
19) Fosun Pharma's Aripiprazole Orally Disintegrating Tablets Receive Drug Registration Approval
On May 9, Fosun Pharma announced that the marketing registration application for Aripiprazole Orally Disintegrating Tablets, independently developed by its holding subsidiary Shanghai Chongqing Youyou Pharmaceutical Co., Ltd. for the treatment of schizophrenia, was recently approved by the National Medical Products Administration.
/ 04 /
Overseas Pharmaceutical News
1) Novartis announces positive results from Phase 3 CONDOR clinical study of Cizumab
On May 9, Novartis announced that the 54-week results of the Phase 3 CONDOR clinical study of brolucizumab 6mg for the treatment of proliferative diabetic retinopathy (PDR) confirmed that brolucizumab significantly outperformed traditional therapies in maintaining vision in PDR patients. It can regress diabetic retinopathy, with the proportion of patients without PDR at week 54 nearly three times that of the control group (63.8% vs 22.4%). In terms of dosing, after 48 weeks, the treatment interval for brolucizumab can be extended based on disease activity assessment, with each extension lasting 6 weeks, up to a maximum of 24 weeks.
2) Avidity Biosciences' Antibody-Conjugated RNAi Therapy Receives Breakthrough Therapy Designation
On May 7, Avidity Biosciences announced that the U.S. FDA had granted the company’s antibody-conjugated RNAi therapy, delpacibart etedesiran, Breakthrough Therapy Designation for the treatment of Type 1 Myotonic Dystrophy (DM1).
Text / Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
